188 related articles for article (PubMed ID: 32731450)
1.
Sidlauskaite E; Le Gall L; Mariot V; Dumonceaux J
J Pers Med; 2020 Jul; 10(3):. PubMed ID: 32731450
[TBL] [Abstract][Full Text] [Related]
2. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
3. Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.
Jones TI; King OD; Himeda CL; Homma S; Chen JC; Beermann ML; Yan C; Emerson CP; Miller JB; Wagner KR; Jones PL
Clin Epigenetics; 2015; 7(1):37. PubMed ID: 25904990
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Strategies Targeting DUX4 in FSHD.
Le Gall L; Sidlauskaite E; Mariot V; Dumonceaux J
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906621
[TBL] [Abstract][Full Text] [Related]
5. Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele.
Haynes P; Bomsztyk K; Miller DG
Epigenetics Chromatin; 2018 Aug; 11(1):47. PubMed ID: 30122154
[TBL] [Abstract][Full Text] [Related]
6. DUX4 promotes transcription of FRG2 by directly activating its promoter in facioscapulohumeral muscular dystrophy.
Thijssen PE; Balog J; Yao Z; Pham TP; Tawil R; Tapscott SJ; Van der Maarel SM
Skelet Muscle; 2014; 4():19. PubMed ID: 25789155
[TBL] [Abstract][Full Text] [Related]
7. Facioscapulohumeral muscular dystrophy.
Tawil R
Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
[TBL] [Abstract][Full Text] [Related]
8. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).
Ansseau E; Vanderplanck C; Wauters A; Harper SQ; Coppée F; Belayew A
Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273791
[TBL] [Abstract][Full Text] [Related]
9. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
[TBL] [Abstract][Full Text] [Related]
10. Facioscapulohumeral muscular dystrophy.
Sacconi S; Salviati L; Desnuelle C
Biochim Biophys Acta; 2015 Apr; 1852(4):607-14. PubMed ID: 24882751
[TBL] [Abstract][Full Text] [Related]
11. Antagonism Between DUX4 and DUX4c Highlights a Pathomechanism Operating Through β-Catenin in Facioscapulohumeral Muscular Dystrophy.
Ganassi M; Figeac N; Reynaud M; Ortuste Quiroga HP; Zammit PS
Front Cell Dev Biol; 2022; 10():802573. PubMed ID: 36158201
[TBL] [Abstract][Full Text] [Related]
12. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.
Statland JM; Tawil R
Curr Opin Neurol; 2011 Oct; 24(5):423-8. PubMed ID: 21734574
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
Haynes P; Kernan K; Zhou SL; Miller DG
Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
[TBL] [Abstract][Full Text] [Related]
14. Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscle.
Campbell AE; Belleville AE; Resnick R; Shadle SC; Tapscott SJ
Hum Mol Genet; 2018 Aug; 27(R2):R153-R162. PubMed ID: 29718206
[TBL] [Abstract][Full Text] [Related]
15. Facioscapulohumeral Muscular Dystrophy.
DeSimone AM; Pakula A; Lek A; Emerson CP
Compr Physiol; 2017 Sep; 7(4):1229-1279. PubMed ID: 28915324
[TBL] [Abstract][Full Text] [Related]
16. Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
Joubert R; Mariot V; Charpentier M; Concordet JP; Dumonceaux J
J Pers Med; 2020 Dec; 11(1):. PubMed ID: 33374516
[TBL] [Abstract][Full Text] [Related]
17. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
Elife; 2015 Jan; 4():. PubMed ID: 25564732
[TBL] [Abstract][Full Text] [Related]
18. Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic
Himeda CL; Jones TI; Jones PL
Mol Ther Methods Clin Dev; 2021 Mar; 20():298-311. PubMed ID: 33511244
[TBL] [Abstract][Full Text] [Related]
19. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
